Claymore Securities Launches Two Unique ETFs

LISLE, Ill.--(BUSINESS WIRE)--Claymore Securities, Inc. today launched two new ETFs: The Claymore/Clear Global Exchanges, Brokers & Asset Managers Index ETF (AMEX: EXB); and the Claymore/Clear Global Vaccine Index ETF (AMEX: JNR). This brings the firm’s total number of ETFs to 25.

“Claymore is committed to bringing financial advisors and their clients access to innovative investment products,” said Christian Magoon, Senior Managing Director of Claymore Securities. “By continuing to partner with best-in-class index providers, such as Clear Indexes LLC, Claymore’s portfolio of ETFs offers today’s investors a broad range of unique investment opportunities.”

Claymore/Clear Global Exchanges, Brokers & Asset Managers Index ETF (AMEX: EXB)

The fund seeks investment results that correspond generally to the performance, before the fund’s fees and expenses, of an index called the Clear Global Exchanges, Brokers & Asset Managers Index. The index is comprised of approximately 100 equity securities traded on global exchanges, as well as American depositary receipts (ADRs) and global depositary receipts (GDRs) of companies that operate a security exchange or brokerage/asset management firm as a primary business. The index is adjusted semi-annually.

Claymore/Clear Global Vaccine Index ETF (AMEX: JNR)

The fund seeks investment results that correspond generally to the performance, before the fund’s fees and expenses, of an equity index called the Clear Global Vaccine Index. The Clear Global Vaccine Index is comprised of equity securities traded on developed market exchanges and American depositary receipts (ADRs) and global depositary receipts (GDRs) of companies that research, develop, manufacture, license, and/or market vaccines. The index is generally comprised of approximately 40 stocks of companies for which the development and distribution of vaccines is a substantial part of their business. The index is rebalanced annually.

About Claymore Securities

Claymore Securities, Inc. is a privately-held financial services company offering unique investment solutions for financial advisors and their valued clients. As of May 31, 2007, Claymore entities have provided supervision, management, servicing or distribution on approximately $17 billion in assets through closed-end funds, unit investment trusts, mutual funds, separately managed accounts and exchanged-traded funds. Claymore Advisors, LLC, an affiliate of Claymore Securities, serves as investment adviser to the funds.

About Clear Indexes

Clear Indexes LLC, a subsidiary of Clear Asset Management, creates and publishes custom indices using a combination of qualitative research and quantitative methods. Clear designs custom indices to quantitatively measure specific market segments. The indices are used for custom institutional benchmarks and investment product design.

Investors should consider the following risk factors and special considerations associated with investing in the respective Funds, which may cause you to lose money.

Investment Risk: An investment in the Fund is subject to investment risk, including the possible loss of the entire principal amount that you invest.

Equity Risk. A principal risk of investing in the Fund is equity risk, which is the risk that the value of the securities held by the Fund will fall due to general market and economic conditions, perceptions regarding the industries in which the issuers of securities held by the Fund participate, or factors relating to specific companies in which the Fund invests. For example, an adverse event, such as an unfavorable earnings report, may depress the value of equity securities of an issuer held by the Fund; the price of common stock of an issuer may be particularly sensitive to general movements in the stock market; or a drop in the stock market may depress the price of most or all of the common stocks and other equity securities held by the Fund. In addition, common stock of an issuer in the Fund’s portfolio may decline in price if the issuer fails to make anticipated dividend payments because, among other reasons, the issuer of the security experiences a decline in its financial condition. Common stock is subordinated to preferred stocks, bonds and other debt instruments in a company’s capital structure, in terms of priority to corporate income, and therefore will be subject to greater dividend risk than preferred stocks or debt instruments of such issuers. In addition, while broad market measures of common stocks have historically generated higher average returns than fixed income securities, common stocks have also experienced significantly more volatility in those returns.

Exchanges, Brokers & Asset Managers Industries Risk (EXB): Because the Index is concentrated in a particular industry, group of industries or sector, the Fund may be adversely affected by the performance of those securities and may be subject to price volatility. In addition, the Fund may be more susceptible to any single economic, market, political or regulatory occurrence affecting that industry or group of industries. Companies in the exchanges, brokers or asset managers industries are subject to extensive government regulation that affects the scope of their activities, the prices they can charge and the amount of capital they must maintain. The exchanges, brokers or asset managers industries can be significantly affected by stock and bond market activity, brokerage commission structures, and a competitive environment combined with the high operating leverage inherent in companies in these industries.

Vaccine Industry Risk (JNR): Companies that research, develop, manufacture, license, and/or market vaccines may be susceptible to government regulation and reimbursement rates. Such companies may also be heavily dependent on patent protection, with their profitability affected by the expiration of patents. Companies that research, develop, manufacture, license, and/or market vaccines may also be subject to expenses and losses from extensive litigation based on product liability and similar claims, as well as competitive forces that may make it difficult to raise prices and, in fact, may result in price discounting. The process for obtaining new product approval by the Food and Drug Administration is long and costly. Such companies also may be characterized by thin capitalization and limited product lines, markets, financial resources or personnel.

Foreign Investment Risk: The Fund’s investments in non-U.S. issuers may involve unique risks compared to investing in securities of U.S. issuers, including, among others, greater market volatility than U.S. securities and less complete financial information than for U.S. issuers. In addition, adverse political, economic or social developments could undermine the value of the Fund’s investments or prevent the Fund from realizing the full value of its investments. Financial reporting standards for companies based in foreign markets differ from those in the United States. Finally, the value of the currency of the country in which the Fund has invested could decline relative to the value of the U.S. dollar, which may affect the value of the investment to U.S. investors. In addition, the underlying issuers of certain depositary receipts, particularly unsponsored or unregistered depositary receipts, are under no obligation to distribute shareholder communications to the holders of such receipts, or to pass through to them any voting rights with respect to the deposited securities.

Non-Correlation Risk: The Fund’s return may not match the return of the Index for a number of reasons. For example, the Fund incurs a number of operating expenses not applicable to the Index, and incurs costs in buying and selling securities, especially when rebalancing the Fund’s securities holdings to reflect changes in the composition of the Index. Since the Index constituents may vary on a semi-annual basis, the Fund’s costs associated with rebalancing may be greater than those incurred by other exchange-traded funds that track indices whose composition changes less frequently. The Fund may not be fully invested at times, either as a result of cash flows into the Fund or reserves of cash held by the Fund to meet redemptions and expenses. If the Fund utilizes a sampling approach or futures or other derivative positions, its return may not correlate as well with the return on the Index, as would be the case if it purchased all of the stocks in the Index with the same weightings as the Index.

Small and Medium-Sized Company Risk: Investing in securities of small and medium-sized companies involves greater risk than is customarily associated with investing in more established companies. These companies’ stocks may be more volatile and less liquid than those of more established companies. These stocks may have returns that vary, sometimes significantly, from the overall stock market.

Replication Management Index: Unlike many investment companies, the Fund is not “actively” managed. Therefore, it would not necessarily sell a stock because the stock’s issuer was in financial trouble unless that stock is removed from the Index.

Issuer-Specific Changes: The value of an individual security or particular type of security can be more volatile than the market as a whole and can perform differently from the value of the market as a whole. The value of securities of smaller issuers can be more volatile than that of larger issuers.

Non-Diversified Fund Risk: The Fund is considered non-diversified and can invest a greater portion of assets in securities of individual issuers than a diversified fund. As a result, changes in the market value of a single investment could cause greater fluctuations in share price than would occur in a diversified fund.

Claymore ETFs are listed on the AMEX the same way as shares of a publicly-traded company. Claymore ETFs can be purchased through most brokerage accounts. They can be bought and sold throughout the day on the AMEX during normal trading hours.

The Fund issues and redeems shares at NAV only in large blocks of 200,000 shares (each block of 200,000 shares is called a “Creation Unit”) or multiples thereof. Only broker-dealers or large institutional investors with creation and redemption agreements, called Authorized Participants (“APs”), can purchase or redeem these Creation Units.

Deliveries of Fund securities to redeeming investors generally will be made within three business days. Due to the schedule of holidays in certain countries, however, the delivery of in-kind redemption proceeds may take longer than three business days after the day on which the redemption request is received in proper form. In such cases, the local market settlement procedures will not commence until the end of the local holiday periods. See the Fund’s SAI for a list of the local holidays in the foreign countries relevant to the Funds.

Investors buying or selling ETF shares on the secondary market may incur brokerage costs and other transactional fees. Shares of ETFs may fluctuate in price due to daily changes in trading volume. At times, shares may not have a high volume of trading. Except when aggregated in Creation Units, Shares are not redeemable securities of the Fund.

Investors should consider the investment objectives and policies, risk considerations, charges and ongoing expenses of the ETFs carefully before they invest. The prospectus contains this and other information relevant to an investment in the ETFs. Please read the prospectus carefully before you invest or send money. For this and more information, please contact a securities representative or Claymore Securities, Inc., 2455 Corporate West Drive, Lisle, Illinois 60532, 800-345-7999 or www.claymore.com/etfs.

NOT FDIC - INSURED • NOT BANK - GUARANTEED • MAY LOSE VALUE

Claymore Securities, Inc.

Member NASD/SIPC 06/07